Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb \/ Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market growth. Multimodal therapy\u2014combining HER2-targeted agents, checkpoint inhibitors, and chemotherapy\u2014has become the standard for HER2- and PD-L1-positive disease. Recently, Imfinzi (AstraZeneca) entered the perioperative setting for gastric cancer, while Vyloy (Astellas), the first-in-class claudin-18.2 inhibitor, is reshaping first-line treatment for HER2-negative patients. In later lines, emerging agents targeting biomarkers such as TROP-2 and B7-H3 are expected to broaden therapeutic options. With a strong late-phase pipeline, additional approvals\u2014such as Ziihera (Jazz Pharmaceuticals)\u2014are anticipated during the forecast period.<\/p>\n
\u00a0<\/p>\n
Questions answered<\/strong><\/p>\n Content highlights<\/strong><\/p>\n Geography:<\/strong> United States, EU5, Japan<\/p>\n Primary research:<\/strong> 19 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research.<\/p>\n Epidemiology:<\/strong> Diagnosed and recurrent incidence of gastroesophageal cancer by country, segmented by stage of disease, histology, HER2 status, and line of therapy<\/p>\n Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key gastroesophageal cancer therapies through 2034, segmented by brands \/ generics \/ biosimilars and drug-treatable populations<\/p>\n Drug treatments:<\/strong> Coverage of key current and emerging therapies<\/p>\n Product description <\/strong><\/p>\n Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n\n
\n